This website uses cookies. By continuing you are agreeing to our privacy policy.

Landon Inge, Ph.D.

Headshot of Landon Inge, Ph.D.
Dignity Health dba St. Joseph's Hospital & Medical Center
Targeting a Cellular Pathway to Treat a Type of Lung Cancer
Lung Cancer Discovery Award

Despite the application of aggressive therapies, lung cancer will lead to more deaths than any other malignancy. Scientists are trying to understand mutations involved in lung cancer in the hopes of developing new therapies. The tumor suppressor gene LKB1 is inactivated frequently in lung cancer. Loss of LKB1 function significantly alters the biology of lung cancer cells and requires LKB1-deficient lung cancer cells to rely on other signaling pathways to assist in maintaining growth and survival. We have evidence that LKB1-deficient lung cancers rely on a specific pathway to assist in survival. Using novel model systems, we will demonstrate that targeting this pathway will lead to a new approach to treat LKB1-deficient lung cancer.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl
What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.